Nymox Corporation

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Nymox Corporation sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,751 sponsors by registered trial count).

6 total trials none currently recruiting 6 completed later-stage tilt upper quartile by trial count

Nymox Corporation: 6 sponsored US clinical trials, none currently recruiting.

Nymox Corporation sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 4 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 1 trials.

Upper-quartile sponsor footprint

Nymox Corporation sits in the upper quartile of the sponsor corpus (#2,085 of 15,751 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

How the Nymox Corporation archive is shaped

6 indexed studies, none listed as recruiting (0% open); 6 completed (100%).

Phase mix: 4 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Prostate Cancer (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.